Ranbaxy Labs advances on launching India’s first NCE, Synriam in African Countries

15 Dec 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 643.80, up by 0.70 points or 0.11 % from its previous closing of Rs. 643.10 on the BSE.

The scrip opened at Rs. 644.90 and has touched a high and low of Rs. 647.55 and Rs. 636.20 respectively. So far, 67266 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 697.50 on 10-Nov-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.

Last one week high and low of the scrip stood at Rs. 654.00 and Rs. 618.25 respectively. The current market cap of the company is Rs. 27362.97 crore.

The promoters holding in the company stood at 63.37 % while Institutions and Non-Institutions held 21.49 % and 13.73 % respectively.

Ranbaxy Laboratories (Ranbaxy) has received the regulatory approval to launch India's first NCE (New Chemical Entity), Synriam (arterolane maleate 150 mg + piperaquine phosphate 750 mg drug) in seven African countries viz. Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast. The product has since been launched in Uganda and will be made available in other countries towards end of January 2015.

The new drug conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Synriam provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 per cent.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.